Remove therapeutic-depth infectious-diseases-vaccines
article thumbnail

Top 30 Pharma and Biotech Companies in 2023: Statistics and Trends

XTalks

With each passing year, pharmaceutical companies around the globe strive to deliver cutting-edge medicines, therapies and vaccines that impact the lives of millions. In this in-depth article, we embark on a captivating journey to uncover the top 30 pharma and biotech companies that have been instrumental in shaping the future of medicine.

Sales 98
article thumbnail

Dr. Reddy’s and GRA announces Avigan Pivotal Studies Update

The Pharma Data

The PRESECO study aims to determine the efficacy of Avigan as an early treatment for COVID-19 patients with mild-to-moderate symptoms, with the goal of alleviating symptoms and preventing disease progression before the infection requires hospitalizations or other intensive interventions. Dr. Reddy’s operates in markets across the globe.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

World RNA Day: What impact RNA it had on drug discovery?  

Drug Discovery World

The NIH states: “This natural mechanism for sequence-specific gene silencing promises to revolutionise experimental biology and may have important practical applications in functional genomics, therapeutic intervention, agriculture and other areas.” There are many examples of ways in which RNAi is impacting drug discovery.

RNA 52
article thumbnail

How big data analytics can make personalised care a reality

Drug Discovery World

These technologies allow researchers to get an unprecedented view of human cellular responses to vaccines, therapeutics, or medical devices and play a crucial role in identifying next-generation diagnostic, predictive, and prognostic biomarkers.

article thumbnail

CARVYKTI® (Ciltacabtagene Autoleucel), Janssen’s First Cell Therapy, for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma

The Pharma Data

Despite recent innovation, new therapeutic approaches are still needed,” said Maria-Victoria Mateos, M.D., Res), EMEA Therapeutic Area Lead Haematology, Janssen-Cilag Limited. About the Janssen Pharmaceutical Companies of Johnson & Johnson At Janssen, we’re creating a future where disease is a thing of the past.